Future Price to Earnings: PepGen (PEPG)
PepGen Inc. possesses high potential due to its proprietary peptide delivery system, which ensures monopoly status. The company's forward P/E ratio demonstrates valuation dynamics, where the value 0.00 represents the current metric. The business relies on the diversification of clinical programs for the treatment of neuropathies. Meanwhile, massive R&D expenditures for oligonucleotide drugs keep the operating leverage in negative territory.
PepGen Corp (PEPG) - metric breakdowns and financial figures
- stock quotes and analyst forecast:
- company stock exchange capitalization indicators:
- balance sheet equity data:
- company total debt and liquidity indicators:
- earnings and market ratios statistics:
PEPG - Net Income|Future Profit PepGen Inc.|PEPG - Business Payback Period|Future Price to Earnings PepGen Inc.|PEPG - Market Cap to Earnings and Growth Ratio|EV/EBITDA Multiple PepGen Inc|PEPG - Profit before interest, taxes and amortization|Earnings per share for the last twelve months PepGen|PEPG - Earnings per one share for the last 12 months|Quarterly EPS earnings growth pepgen.com|PEPG - Net earnings per share change in current year|Net earnings per share growth forecast for next year PepGen Inc.
Fundamental valuation:PepGen
PepGen Inc. is developing a biopharmaceutical platform through strategic partnerships with industry behemoths, as it lacks its own funds for mergers. By analyzing the company's forward P/E ratio, an investor assesses the current share price relative to the projected net income for the coming year, which helps determine the extent of the asset's premium and minimizes the risk of investing in an overvalued instrument.
Main competitors
Forward P/E Multiple BIIB|NBIX - Projected Price to Earnings Ratio|Future Price to Earnings Regencell RGC|AXSM (Axsome Corp) - Price to Expected Earnings Ratio|ACADIA Pharmaceuticals - Forward P/E Multiple|Forward Price to Earnings Multiple xenon-pharma.com (XENE)|VKTX: Forward P/E Multiple|Projected Price to Earnings Ratio Supernus Pharmaceuticals, Inc. (SUPN)|Future Price to Earnings Catalyst Pharmaceuticals Inc|Price to Future Earnings Ratio DNLI (Denali Corp)|Projected Price to Earnings HRMY (Harmony Biosciences)|BHVN (biohavenpharma.com) - Future Price to Earnings Multiple|Forward P/E Multiple AMLX (Amylyx Pharmaceuticals, Inc.)|Market Cap to Projected Earnings Trevi Therapeutics Inc (TRVI)|PRAX - Future Price to Earnings|AVXL (Anavex Life Sciences Corp) - Price to Future Earnings Ratio|CBLL: Forward P/E Multiple|Projected Price to Earnings Prothena|Projected Price to Earnings ALEC|Annexon Biosciences (ANNX) - Market Cap to Projected Earnings|Future Price to Earnings Omeros Corporation (OMER)|NGNE: Price to Expected Earnings Ratio|Forward P/E Multiple ACIU (AC Immune)|voyagertherapeutics.com (VYGR) - Projected Price to Earnings Ratio|NMRA - Future Price to Earnings|Price to Expected Earnings Ratio SCLX|TVGN: Forward P/E Multiple|Forward Price to Earnings Multiple Alpha Cognition Inc. ACOG|Future Price to Earnings Cognition Therapeutics|Price to Future Earnings Ratio IKT (inhibikase.com)|Forward P/E Multiple SAVA|ASRT - Projected Price to Earnings Ratio|Coya Therapeutics - Projected Price to Earnings|Forward P/E Multiple VistaGen Therapeutics, Inc. VTGN|OVID - Future Price to Earnings|Future Price to Earnings Multiple ABOS (acumenpharm.com)|CervoMed (CRVO) - Future Price to Earnings|Projected Price to Earnings Ratio Alterity Therapeutics Limited (ATHE)|Future Price to Earnings Clene Inc|Jupiter Neurosciences, Inc. - Price to Expected Earnings Ratio|Forward P/E Multiple RLMD|ANVS - Projected Price to Earnings Ratio|Future Price to Earnings Grace Therapeutics GRCE|AIFF (Firefly Neuroscience, Inc.) - Price to Expected Earnings Ratio|ANEW Medical, Inc. - Forward P/E Multiple|Forward Price to Earnings Multiple NeuroSense Therapeutics (NRSN)|RVPH: Forward P/E Multiple|Projected Price to Earnings Ratio MetaVia (MTVA)|Future Price to Earnings NeurAxis|Price to Future Earnings Ratio HSDT (Helius Medical Technologies Inc.)|Projected Price to Earnings PASG (Passage Bio, Inc.)|NEUP (bionomics.com.au) - Future Price to Earnings Multiple|Forward P/E Multiple NERV (Minerva Neurosciences)|Market Cap to Projected Earnings athira.com (ATHA)|ADXN - Future Price to Earnings|ALZN (Alzamend Neuro, Inc.) - Price to Future Earnings Ratio|CYCN: Forward P/E Multiple|Projected Price to Earnings Protagenic Therapeutics, Inc.|Projected Price to Earnings KTTA|Cortigent Medical (CRGT) - Market Cap to Projected Earnings|Future Price to Earnings Avenue Therapeutics, Inc. (ATXI)|BCLI: Price to Expected Earnings Ratio|Forward P/E Multiple CARA (Cara Therapeutics, Inc)|Chromocell (CHRO) - Projected Price to Earnings Ratio|ELYM - Future Price to Earnings|Price to Expected Earnings Ratio ITCI|LBPH: Forward P/E Multiple|Forward Price to Earnings Multiple Marinus Pharmaceuticals Inc MRNS|Future Price to Earnings NKGen|Price to Future Earnings Ratio NRBO (NeuroBo Pharma)|Forward P/E Multiple SAGE|SNPX - Projected Price to Earnings Ratio|Trevena - Projected Price to Earnings|Forward P/E Multiple Vigil Neuroscience Inc. VIGL|WENA - Future Price to Earnings|Future Price to Earnings Multiple CERE (Cerevel Corp)
